Orgenesis Inc. (ORGS)
USD 2.4
(10.6%)
USD 2.4
(10.6%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 19.06 Million USD | 25.72% |
| 2022 | 15.16 Million USD | 177.97% |
| 2021 | 5.45 Million USD | -34.14% |
| 2020 | 8.28 Million USD | -61.62% |
| 2019 | 21.58 Million USD | 699.44% |
| 2018 | 2.7 Million USD | -40.44% |
| 2017 | 4.53 Million USD | 4.21% |
| 2016 | 4.35 Million USD | 71.26% |
| 2015 | 2.54 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 8.05 Million USD | -65.01% |
| 2024 Q1 | 23.03 Million USD | 21.43% |
| 2023 Q1 | 19.51 Million USD | 28.69% |
| 2023 FY | 19.06 Million USD | 25.72% |
| 2023 Q2 | 18.03 Million USD | -7.61% |
| 2023 Q3 | 18.54 Million USD | 2.83% |
| 2023 Q4 | 19.06 Million USD | 2.83% |
| 2022 Q4 | 15.16 Million USD | 165.7% |
| 2022 Q3 | 5.7 Million USD | -60.15% |
| 2022 Q1 | 8.04 Million USD | 47.38% |
| 2022 FY | 15.16 Million USD | 177.97% |
| 2022 Q2 | 14.32 Million USD | 78.14% |
| 2021 Q3 | 7.98 Million USD | 45.25% |
| 2021 Q4 | 5.45 Million USD | -31.71% |
| 2021 Q2 | 5.5 Million USD | -31.54% |
| 2021 FY | 5.45 Million USD | -34.14% |
| 2021 Q1 | 8.03 Million USD | -3.02% |
| 2020 Q2 | 10.7 Million USD | -4.82% |
| 2020 FY | 8.28 Million USD | -61.62% |
| 2020 Q1 | 11.24 Million USD | -47.91% |
| 2020 Q3 | 11.24 Million USD | 5.07% |
| 2020 Q4 | 8.28 Million USD | -26.33% |
| 2019 Q1 | 15.2 Million USD | 463.3% |
| 2019 Q2 | 18.01 Million USD | 18.48% |
| 2019 Q4 | 21.58 Million USD | 22.03% |
| 2019 FY | 21.58 Million USD | 699.44% |
| 2019 Q3 | 17.68 Million USD | -1.84% |
| 2018 Q3 | 1.8 Million USD | -5.36% |
| 2018 FY | 2.7 Million USD | -40.44% |
| 2018 Q4 | 2.7 Million USD | 50.0% |
| 2018 Q2 | 1.9 Million USD | -25.91% |
| 2018 Q1 | 2.56 Million USD | -43.37% |
| 2017 FY | 4.53 Million USD | 4.21% |
| 2017 Q2 | 5.05 Million USD | 1.26% |
| 2017 Q1 | 4.99 Million USD | 14.78% |
| 2017 Q4 | 4.53 Million USD | -6.36% |
| 2017 Q3 | 4.84 Million USD | -4.25% |
| 2016 FY | 4.35 Million USD | 71.26% |
| 2016 Q4 | 4.35 Million USD | 28.47% |
| 2016 Q1 | 2.53 Million USD | -0.24% |
| 2016 Q2 | 2.51 Million USD | -0.79% |
| 2016 Q3 | 3.38 Million USD | 34.69% |
| 2015 FY | 2.54 Million USD | 0.0% |
| 2015 Q2 | 5.59 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | 5.32 Million USD | -4.91% |
| 2015 Q4 | 2.54 Million USD | -52.26% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -1597.654% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -1375.774% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 56.404% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -190570.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | -84.258% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -13919.853% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -15749.279% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -119.363% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 60.991% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -409.303% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 32.87% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 87.377% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -8606.432% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -1991.827% |
| Molecular Templates, Inc. | 9.74 Million USD | -95.72% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -918.691% |
| NexImmune, Inc. | - USD | -Infinity% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -354.626% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 81.726% |
| Statera Biopharma, Inc. | 11.43 Million USD | -66.799% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -2504.781% |
| Trevena, Inc. | 35.23 Million USD | 45.883% |
| Vaxxinity, Inc. | 13.26 Million USD | -43.772% |
| Vaccinex, Inc. | 26 Thousand USD | -73234.615% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |